Ribociclib & NSAI: Improved Breast Cancer Outcomes & Productivity
- Chicago, Illinois—The addition of ribociclib to a nonsteroidal aromatase inhibitor (NSAI) as adjuvant therapy for hormone receptor-positive (HR+), human epidermal growth receptor 2-negative (HER2-) early breast cancer not...
- women would be diagnosed with breast cancer in 2024, with approximately 42,000 deaths.
Ribociclib, a primary_keyword, when combined with a nonsteroidal aromatase inhibitor (NSAI), considerably boosts work productivity for HR+/HER2- early breast cancer patients, according to recent findings. This treatment not only improves invasive disease-free survival but also offers substantial economic benefits, with societal gains estimated at $637.7 million.News Directory 3 reports on how this combination is transforming outcomes for over 300,000 women diagnosed annually, addressing the secondary_keyword of cancer recurrence risk.Discover what’s next in this critical area of breast cancer treatment.
Ribociclib Treatment Boosts Productivity in Breast Cancer Patients
Updated June 14, 2025
Chicago, Illinois—The addition of ribociclib to a nonsteroidal aromatase inhibitor (NSAI) as adjuvant therapy for hormone receptor-positive (HR+), human epidermal growth receptor 2-negative (HER2-) early breast cancer not only extends invasive disease-free survival (iDFS) but also enhances work productivity, according to findings presented at the American Society of Clinical Oncology Annual Meeting.
The American Cancer Society estimates over 300,000 U.S. women would be diagnosed with breast cancer in 2024, with approximately 42,000 deaths. The HR+/HER2- subtype is the most prevalent, accounting for about 70% of new cases. thes patients face a higher risk of cancer recurrence, often as incurable metastatic disease.
The Food and drug Administration (FDA) approved ribociclib in September 2024 for use with an aromatase inhibitor in patients with stage II and III HR+/HER2- early breast cancer at high recurrence risk.This approval stemmed from the phase 3 NATALEE trial,